{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:27:23Z","timestamp":1790263643690,"version":"4.1.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1038\/ajg.2017.287","type":"journal-article","created":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T08:01:33Z","timestamp":1507622493000},"page":"49-55","source":"Crossref","is-referenced-by-count":109,"title":["Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response"],"prefix":"10.14309","volume":"113","author":[{"given":"Anna","family":"Reig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Ses\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Par\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210210","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/ajg.2015.312","article-title":"Changing nomenclature for PBC: from cirrhosis to cholangitis.","volume":"110","author":"Beuers","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"R2-13-20210210","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(15)00154-3","article-title":"Primary biliary cirrhosis.","volume":"386","author":"Carey","year":"2015","journal-title":"Lancet"},{"key":"R3-13-20210210","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","article-title":"EASL Clinical Practice Guidelines: management of cholestatic liver diseases.","volume":"51","year":"2009","journal-title":"J Hepatol"},{"key":"R4-13-20210210","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1055\/s-0036-1597929","article-title":"Novel treatment strategies for primary biliary cholangitis.","volume":"37","author":"Pares","year":"2017","journal-title":"Semin Liver Dis"},{"key":"R5-13-20210210","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis.","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"R6-13-20210210","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1111\/j.1572-0241.2000.03220.x","article-title":"Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid.","volume":"95","author":"Kurihara","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R7-13-20210210","first-page":"1518","article-title":"A novel treatment for refractory primary biliary cirrhosis?","volume":"47","author":"Miyaguchi","year":"2000","journal-title":"Hepatogastroenterology"},{"key":"R8-13-20210210","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2000.01667.x","article-title":"Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study.","volume":"95","author":"Nakai","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R9-13-20210210","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1034\/j.1600-0676.2001.021003223.x","article-title":"Effect of bezafibrate in primary biliary cirrhosis: a pilot study.","volume":"21","author":"Ohmoto","year":"2001","journal-title":"Liver"},{"key":"R10-13-20210210","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1572-0241.2002.05645.x","article-title":"Is bezafibrate histologically effective for primary biliary cirrhosis?","volume":"97","author":"Yano","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R11-13-20210210","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/j.1572-0241.2002.05944.x","article-title":"Fenofibrate treatment in patients with primary biliary cirrhosis.","volume":"97","author":"Ohira","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R12-13-20210210","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00535-002-1102-7","article-title":"Bezafibrate treatment: a new medical approach for PBC patients?","volume":"38","author":"Kanda","year":"2003","journal-title":"J Gastroenterol"},{"key":"R13-13-20210210","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3748\/wjg.v10.i6.894","article-title":"Fenofibrate for patients with asymptomatic primary biliary cirrhosis.","volume":"10","author":"Dohmen","year":"2004","journal-title":"World J Gastroenterol"},{"key":"R14-13-20210210","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.hepres.2004.04.001","article-title":"Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis.","volume":"29","author":"Itakura","year":"2004","journal-title":"Hepatol Res"},{"key":"R15-13-20210210","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1872-034X.2007.00305.x","article-title":"The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study.","volume":"38","author":"Iwasaki","year":"2008","journal-title":"Hepatol Res"},{"key":"R16-13-20210210","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/hep.22670","article-title":"Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.","volume":"49","author":"Walker","year":"2009","journal-title":"Hepatology"},{"key":"R17-13-20210210","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/MCG.0b013e3181c115b3","article-title":"Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid.","volume":"44","author":"Hazzan","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"R18-13-20210210","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2010.04512.x","article-title":"Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.","volume":"33","author":"Levy","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"R19-13-20210210","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/hep.26018","article-title":"Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.","volume":"57","author":"Honda","year":"2013","journal-title":"Hepatology"},{"key":"R20-13-20210210","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/liv.12290","article-title":"Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid.","volume":"34","author":"Lens","year":"2014","journal-title":"Liver Int"},{"key":"R21-13-20210210","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ajg.2015.20","article-title":"A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia.","volume":"110","author":"Hosonuma","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"R22-13-20210210","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid.","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"key":"R23-13-20210210","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2014.01.029","article-title":"Optimising risk stratification in primary biliary cirrhosis: ASTplatelet ratio index predicts outcome independent of ursodeoxycholic acid response.","volume":"60","author":"Trivedi","year":"2014","journal-title":"J Hepatol"},{"key":"R24-13-20210210","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy.","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"R25-13-20210210","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis.","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"key":"R26-13-20210210","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2133.2009.09586.x","article-title":"The 5-D itch scale: a new measure of pruritus.","volume":"162","author":"Elman","year":"2010","journal-title":"Br J Dermatol"},{"key":"R27-13-20210210","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/hep.25599","article-title":"Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis.","volume":"56","author":"Corpechot","year":"2012","journal-title":"Hepatology"},{"key":"R28-13-20210210","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/apt.13465","article-title":"Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes.","volume":"43","author":"Cheung","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R29-13-20210210","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1007\/s10620-016-4250-y","article-title":"Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but not the UK-PBC risk score.","volume":"61","author":"Hegade","year":"2016","journal-title":"Dig Dis Sci"},{"key":"R30-13-20210210","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/S0168-8278(17)30442-7","article-title":"A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso).","volume":"66","author":"Corpechot","year":"2017","journal-title":"J Hepatol"},{"key":"R31-13-20210210","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/hep.27744","article-title":"Fibrates and cholestasis.","volume":"62","author":"Ghonem","year":"2015","journal-title":"Hepatology"},{"key":"R32-13-20210210","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/347645a0","article-title":"Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators.","volume":"347","author":"Issemann","year":"1990","journal-title":"Nature"},{"key":"R33-13-20210210","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0022-2275(20)42003-6","article-title":"Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression.","volume":"37","author":"Schoonjans","year":"1996","journal-title":"J Lipid Res"},{"key":"R34-13-20210210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.taap.2008.03.007","article-title":"PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes.","volume":"231","author":"Thulin","year":"2008","journal-title":"Toxicol Appl Pharmacol"},{"key":"R35-13-20210210","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00228-003-0704-1","article-title":"Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients.","volume":"59","author":"Roglans","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"R36-13-20210210","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.hepres.2004.08.015","article-title":"Multidrug resistance3 is in situ detected in the liver of patients with primary biliary cirrhosis, and induced in human hepatoma cells by bezafibrate.","volume":"30","author":"Matsumoto","year":"2004","journal-title":"Hepatol Res"},{"key":"R37-13-20210210","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1042\/bj3140781","article-title":"Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse.","volume":"314","author":"Chianale","year":"1996","journal-title":"Biochem J"},{"key":"R38-13-20210210","first-page":"529A","article-title":"Long term impact of fibrates in primary sclerosing cholangitis with incomplete biochemical response to ursodeoxycholic acid. The French-Spanish experience.","volume":"62","author":"Lemoinne","year":"2015","journal-title":"Hepatology"},{"key":"R39-13-20210210","first-page":"S429","article-title":"Bezafibrate alleviates pruritus and decreases specific circulating metabolites in patients with primary biliary cholangitis.","volume":"64","author":"Reig","year":"2016","journal-title":"J Hepatol"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00000434-201801000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:20:24Z","timestamp":1786548024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201801000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2017.287","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}